CAMP4 THERAPEUTICS CORPORATION (CAMP) News
Follow CAMP4 THERAPEUTICS CORPORATION (CAMP) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
CAMP4 Therapeutics Is Maintained at Buy by Chardan Capital
Ratings actions from Benzinga: GMT) CAMP4 Therapeutics Price Target Cut to $6.00/Share From $6.50 by Chardan CapitalRatings actions from Benzinga
NEWS | Sep 29, 2026, 12:19 PM UTC
L
Chardan Capital maintains Buy rating on Camp4 Therapeutics, $6 price target
Chardan Capital maintained their Buy rating on Camp4 Therapeutics's stock with a price target of $6.00.The price target implies an upside of 55.8% from the Sep 28 close of $3.85.Key takeaways from the analyst noteStrong
EQUITY | Sep 29, 2026, 12:08 PM UTC
L
Camp4 Therapeutics outlines Phase 1/2 ASCEND trial plan for CMP-002, first patient dosing by end of 2026
Camp4 Therapeutics announced design and timelines for its Phase 1/2 ASCEND trial of CMP-002, targeting first patient dosing by end of 2026.Key Highlights:Original SEC Filing: Camp4 Therapeutics Corp [ CAMP ] - 8-K - Sep.
REGULATION | Sep 28, 2026, 08:56 PM UTC
L
CAMP4 Therapeutics receives UK authorization for Phase 1/2 CMP-002 trial
Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4’s recent clearances to initiate first-in-human studies for CMP-002 in Australia and ArgentinaCompany anticipates init
EQUITY | Sep 10, 2026, 11:42 AM UTC
M
CAMP Phase I SYNGAP1 trial authorized to start in Q4
CAMP’s upcoming Phase I SYNGAP1 trial in multiple countries is authorized to begin in Q4. The multi-cohort study will use preclinical and natural history data, with endpoints across cognitive, motor and seizure domains.
EQUITY | Sep 09, 2026, 06:50 PM UTC
L
CAMP4 Therapeutics to host virtual analyst day Sept. 28, 2026
CAMP4 Therapeutics says it will host a virtual analyst day on September 28, 2026 to discuss CMP-002 for SYNGAP1-related disorder treatment.
EQUITY | Sep 08, 2026, 08:05 PM UTC
L
CAMP - CAMP4 to Participate in Upcoming Investor Conferences
CAMP - CAMP4 to Participate in Upcoming Investor Conferences
EQUITY | Sep 01, 2026, 08:05 PM UTC
M
Canadian GoldCamps completes initial 85% acquisition in Stealthwall West project
Canadian GoldCamps has completed its acquisition of an initial 85% interest in the Stealthwall West gold project in northeastern Québec.
COMMODITIES | Aug 31, 2026, 09:05 PM UTC
L
CAMP4 reports second-quarter 2026 financial results
CAMP4 reports second-quarter 2026 financial results and corporate highlights.
EARNINGS | Aug 13, 2026, 08:06 PM UTC
H
CAMP4 Therapeutics Raises $100M
CAMP4 Therapeutics raises $100M in private placement
EQUITY | Aug 04, 2026, 11:01 AM UTC